GLYCOSYLATION PRODUCTS AS TOXIC MEDIATORS OF DIABETIC COMPLICATIONS

被引：76

作者：

BROWNLEE, M

机构：

[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461

[2] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIABET RES CTR,BRONX,NY 10461

来源：

ANNUAL REVIEW OF MEDICINE | 1991年 / 42卷

关键词：

DIABETES; EXTRACELLULAR MATRIX; MACROPHAGES; GROWTH FACTORS; COAGULATION; DNA; PHARMACOLOGY; THERAPY; AMINOGUANIDINE;

D O I：

10.1146/annurev.med.42.1.159

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Hyperglycemia causes excessive amounts of irreversible advanced glycosylation end products (AGEPs) to accumulate on long-lived extracellular matrix proteins and probably also on DNA in tissues that develop diabetic complications. AGEPs induce permanent abnormalities in extracellular protein cross-linking, cell-matrix interactions, and DNA structure in vitro. Pharmacologically inhibiting AGEP formation in long-term diabetic animals prevents both retinal capillary pathology and thickening of the glomerular basement membrane.

引用

页码：159 / 166

页数：8

共 32 条

[11]

CROWLEY S, 1990, IN PRESS DIABETES, V39

[12]

ELLIS EN, 1990, DIABETES S1, V39, pA71

[13] PROGRESSION OF INCIPIENT DIABETIC-RETINOPATHY DURING GOOD GLYCEMIC CONTROL [J].